Scil Proteins receives EMA approval for commercial production of Reteplase

Published: 23-Oct-2012
Ingredients Cardiovascular Pharmaceutical

The recombinant protein will be produced in Halle, Germany


The European Medicines Agency (EMA) has approved Scil Proteins’ Halle, Germany facilities for the manufacture of Reteplase, which is marketed by Actavis as Rapilysin.

The private German biotech specialist in the research, development and production of recombinant proteins originally signed an agreement with Roche in June 2008 for process transfer and manufacture of Reteplase and with this approval from the European regulator, it has successfully completed the site change from Roche. Reteplase is a recombinant protein for thrombolytic treatment of myocardial infarction.

Ulrike Fiedler, CEO of Scil Proteins, said: ‘Our focus on quality enabled our experienced team of protein specialists to readily manage the manufacturing challenges of this complex biotherapeutic. We have the proven expertise and capacity to allow us to produce a number of advanced biotherapeutics and this EMA approval for our Halle facility is an important milestone for Scil Proteins.’

  • Companies:
  • Scil Proteins GmbH / Navigo Proteins
See more

You may also like

Manufacturing

Wacker acquires Scil Proteins Production

Read more
The transaction will create a leading microbial-based biopharmaceutical manufacturer

Trending Articles

  1. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  2. Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  5. Production of pharmaceutical compounds through microbial fermentation Most people’s experience of fermentation will be through its most famous and popular use – the brewing of beer

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Manufacturing

Wacker acquires Scil Proteins Production

The transaction will create a leading microbial-based biopharmaceutical manufacturer
Cardiovascular

Scil Proteins to manufacture Reteplase for Actavis

Reteplase is the active ingredient in heart attack drug Rapilysin
Research & Development

Scil Proteins signs partnership to research cancer therapies

Will work with Martin Luther University Halle-Wittenberg
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Subscribe now